R. Troyan
3 Papers
R. Troyan is an academic researcher. The author has contributed to research in topics: Antibody & Immunology. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Prospective evaluation of COVID-19 vaccine responses across a broad spectrum of immunocompromising conditions: the COVICS study.
Ghady Haidar,Mounzer E. Agha,Andrew Bilderback,Amy Lukanski,Kelsey Linstrum,R. Troyan,Scott D. Rothenberger,Deborah McMahon,Melissa D Crandall,M. Sobolewksi,P. Nathan Enick,Jana L. Jacobs,Kevin Collins,Cynthia Klamar-Blain,Bernard J.C. Macatangay,Urvi M. Parikh,Amy Heaps,Lindsay Coughenour,Marc Schwartz,Jeff Dueker,Fernanda P. Silveira,Mary E. Keebler,Abhinav Humar,James D. Luketich,Matthew R. Morrell,Joseph M. Pilewski,John F. McDyer,Bhanu P. Pappu,Robert L. Ferris,Stanley M. Marks,J.R. Mahon,Katie Mulvey,Sundaram Hariharan,Glenn Updike,Lorraine Brock,R.E. Edwards,Richard H. Beigi,P. L. Kip,Alan Wells,Tami Minnier,Derek C. Angus,John W. Mellors +41 more
TL;DR: Antibody responses to COVID-19 vaccines were lowest among SOT and anti-CD20 monoclonal recipients, and recipients of vaccines other than mRNA-1273, and among those with intermediate antibody levels, pseudovirus neutralization titers were lower in immunocompromised patients than HCW.
51
Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS)
Ghady Haidar,Mounzer E. Agha,Andrew Bilderback,Amy Lukanski,Kelsey Linstrum,R. Troyan,Scott D. Rothenberger,Deborah McMahon,Melissa D Crandall,M. Sobolewksi,P. Nathan Enick,Jana L. Jacobs,Kevin Collins,Cynthia Klamar-Blain,Bernard J.C. Macatangay,Urvi M. Parikh,Amy Heaps,Lindsay Coughenour,Marc B Schwartz,Jeff Dueker,Fernanda P. Silveira,Mary E. Keebler,Abhinav Humar,James D. Luketich,Matthew R. Morrell,Joseph M. Pilewski,John F. McDyer,Bhanu P. Pappu,Robert L. Ferris,Stanley M. Marks,J.R. Mahon,Katie Mulvey,Sundaram Hariharan,Glenn Updike,Lorraine Brock,R.E. Edwards,Richard H. Beigi,P. L. Kip,Alan Wells,Tami Minnier,Derek C. Angus,John W. Mellors +41 more
TL;DR: Antibody responses to COVID-19 vaccines were lowest among SOT and anti-CD20 monoclonal recipients, and recipients of vaccines other than mRNA-1273, and among those with intermediate antibody levels, pseudovirus neutralization titers were lower in immunocompromised patients than HCWs.
Prospective assessment of humoral and cellular immune responses to a 3rd COVID-19 mRNA vaccine dose among immunocompromised individuals.
Ghady Haidar,Jacob C Hodges,Andrew L Bilderback,Amy Lukanski,Kelsey Linstrum,Barbara Postol,R. Troyan,Mary Kay Wisniewski,Lindsay Coughenour,Amy Heaps,Jana L. Jacobs,K. Hughes Kramer,Cynthia Klamar-Blain,Joshua Kohl,Wendy Liang,Benjamin Morris,Bernard J.C. Macatangay,Urvi M. Parikh,M. Sobolewksi,Christopher Musgrove,Melissa D Crandall,John Mahon,Katie Mulvey,Kevin Collins,Adam C King,Alan Wells,Rachel Zapf,Mounzer E. Agha,Tami Minnier,Derek C Angus,John W. Mellors +30 more
TL;DR: D3 significantly improves serological but not T-cell responses among immunocompromised individuals, and SOT and HM patients have suboptimal responses to D3.